Pacific Biosciences Of California (PACB) Other Non-Current Liabilities (2010 - 2026)

Pacific Biosciences Of California's Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $8.0 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $18.7 million, up 2390.01% from the prior year.
• Other Non-Current Liabilities declined to $8.0 million in Q1 2026 per PACB's latest filing, from $18.7 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $184.4 million in Q1 2023 and bottomed at $751000.0 in Q4 2023.
• The 4-year median for Other Non-Current Liabilities is $18.4 million (2023), against an average of $46.7 million.
• Across the five-year window, Other Non-Current Liabilities jumped 21604.26% in 2022 and sank 99.59% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $1.3 million in 2022, then sank by 42.23% to $751000.0 in 2023, then soared by 2390.01% to $18.7 million in 2024, then slumped by 57.22% to $8.0 million in 2026.
• Per Business Quant, the three latest PACB Other Non-Current Liabilities figures stand at $8.0 million (Q1 2026), $18.7 million (Q4 2024), and $20.6 million (Q3 2024).